1. Introduction {#sec1}
===============

Chromosomal instability is characterized by changes in chromosome copy number (aneuploidy) and alterations in chromosomal regions, which may induce oncogene activation, tumor suppressor gene inactivation, or both. Chromosomal instability is one of the two major genomic instability pathways observed in gastric cancer (GC) \[[@B1]\], the fourth most frequent type of cancer and second most frequent cause of cancer mortality worldwide \[[@B2]\]. However, due to the difficulty in obtaining high-quality chromosome preparations in these neoplasias, the evaluation of chromosomal alterations is complicated \[[@B3]--[@B7]\].

Cell lines derived from human cancers are useful in order to understand the chromosomal alterations and other molecular alterations in the carcinogenesis process. Cell lines are also a useful tool for the study of anticancer treatments *in vitro* and in animal xenograft models. However, the process of cell line immortalization has been implicated as a source of cytogenetic changes, and growth passages have been associated with random genomic instability \[[@B8]--[@B11]\]. Given their importance as models, it is important to understand in which way and to what degree cell lines grown under artificial conditions reflect their parental *in vivo* genetic architecture \[[@B8]\].

Our research group previously established three GC cell lines from tumor samples of individuals from Northern Brazil. ACP02 cell line was established from a diffuse-type GC, and ACP03 and AGP01 were from an intestinal-type GC. These cell lines exhibited a composite karyotype with several clonal chromosomal alterations. All these cell lines presented chromosome 8 trisomy---where *MYC* oncogene is located---and deletion of chromosome arm 17p, which includes the *TP53*tumor suppressor locus. Moreover, chromosome 17 (chr17) trisomy in ACP03 and AGP01 cell lines was detected \[[@B12]\].

Here, we analyzed the number of *MYC*, *TP53,* and chr17 copies in 6th (short-duration culture), 12th (long-duration culture), 60th and 85th passages of ACP02, ACP03 and AGP01 cell lines, and in their parental primary tumors. We aim to evaluate whether these gene/chromosomal alterations occur in cell lines and in their tumor counterpart, as well as whether multiple passage growth leads to a difference in the frequency of these alterations.

2. Materials and Methods {#sec2}
========================

FISH was performed on recently made slides from methanol/acetic acid fixed cells of four passages (6th, 12th, 60th, and 85th) of ACP02, ACP03, and AGP01 cell lines, as previously described \[[@B13]\]. FISH was also applied on nuclei isolated from parental primary tumors as previously reported \[[@B14]\]. Tumor samples were obtained from João de Barros Barreto University Hospital (HUJBB) in Pará State, Brazil.

To determine *MYC* gene copy number, cells were hybridized with a rhodamine-labeled probe (Chromotrax, USA) for *MYC* gene region (8q24.1-q24.2). To determine the chromosome 17 and *TP53*copy numbers, cells were hybridized using a dual-color direct labeled probe (Qbiogene, USA) specific for chr17 *α*-satellite and for *TP53*gene region, and labeled with fluorescein and rhodamine, respectively. Nuclei were counterstained with DAPI/antifade (Chemicon, USA). Fluorescence was detected using an Olympus BX41 fluorescence microscope with DAPI/FITC/TRICT filters (Olympus, Japan), and signals were analyzed using FISHView of Applied Spectral Imaging image analysis system (ASI Ldt., Israel). For each cell line or tumor, 200 interphase nuclei were analyzed and scored using the criteria of Hopman et al. \[[@B15]\]. To avoid misinterpretation due to technical error, gastric mucosal tissue (nonneoplastic) and normal lymphocyte nuclei were used as control.

For statistical analysis, the *MYC*, *TP53,* or chr17 copy numbers were compared among cell lines using Kruskal-Wallis nonparametric test followed by Games-Howell posthoc test. Friedman test followed by Wilcoxon posthoc test with Bonferroni correction were used to evaluate differences among primary tumor and their cell line passages. In all analyses, the confidence interval was 95%, and *P* values less than  .05 were considered significant.

3. Results {#sec3}
==========

3.1. MYC {#sec3.1}
--------

Two signals for *MYC* probe were observed in 99.5% of peripheral blood lymphocytes and in 97% of normal gastric cells ([Figure 1(a)](#fig1){ref-type="fig"}). [Table 1](#tab1){ref-type="table"} shows the frequency of *MYC* signals in cell lines and parental tumors. In primary tumor samples, three *MYC* signals were the most frequent alteration, ranging from 39%--45% of cells ([Figure 1(b)](#fig1){ref-type="fig"}). In the 6th and 12th passages, 3 *MYC* signals were the most frequent alteration (about 40%) followed by 4 signals (about 28%). In the 60th passage of cell lines, 3 and 4 *MYC* signals were commonly observed. In the 85th passage, the most frequent alteration was the presence of 4 signals for *MYC* probe, ranging from 33.5%--42% of cells. Five or more *MYC* copies by cells were also observed in all cell lines and parental tumors. High amplification of *MYC* was detected as clonal alteration mainly in cell lines ([Figure 1(c)](#fig1){ref-type="fig"}).

Statistical analysis revealed that the frequency of cells with high *MYC* amplification was significantly different among ACP02, ACP03, and AGP01 cell lines (*χ*^2^ = 9.206, df = 2, *P* = .01, by Kruskal-Wallis test). The Games-Howell posthoc analyses demonstrated that the ACP02, cell line, and parental tumor, presented a lower frequency of high *MYC* amplification cells than AGP01 (*P* = .019) and ACP03 (*P* = .014).

Concerning the *MYC* signal frequency during culture process, we observed that the frequency of cells with 2 (*χ*^2^ = 10.933, df = 4, *P* = .027, by Friedman test), 4 (*χ*^2^ = 10.667, df = 4, *P* = .031, by Friedman Test), 5 or more (*χ*^2^ = 11.467, df = 4, *P* = .022, by Friedman test), and high amplification (*χ*^2^ = 11.429, df = 4, *P* = .022, by Friedman test) *MYC* copies were significantly different among parental tumor and their passages. However, the posthoc analysis by Wilcoxon test with Bonferroni correction did not reveal any significant difference, probably due to the gradual alterations among passages (Figures [2(a)](#fig2){ref-type="fig"}, [2(b)](#fig2){ref-type="fig"}, [2(c)](#fig2){ref-type="fig"}, [2(d)](#fig2){ref-type="fig"}).

3.2. Chr17/TP53 {#sec3.2}
---------------

Two signals for chr17 and *TP53*were observed in about 97% of control cells ([Figure 1(d)](#fig1){ref-type="fig"}). [Table 2](#tab2){ref-type="table"} shows the frequency of chr17/*TP53* signals in cell lines from the 6th, 12th, 60th, and 85th passages and tumor samples.

The frequency of cells with 2 signals for chr17 and 2 signals for *TP53* was significantly different among ACP02, ACP03, and AGP01 cell lines (*χ*^2^ = 6, df = 2, *P* = .05, by Kruskal-Wallis test). The Games-Howell posthoc analyses demonstrated that the ACP02, cell line, and parental tumor presented a higher number of this cell type than AGP01. ACP02 also presented a higher frequency of cells with two copies of chr17 than AGP01 (*P* = .003, by Games-Howell posthoc analysis) and ACP03 (*P* = .009, by Games-Howell posthoc analysis).

The frequency of cells with 2/1 (*χ*^2^ = 10.839, df = 2, *P* = .004, by Kruskal-Wallis test), 2/3 (*χ*^2^ = 11.423, df = 2, *P* = .003, by Kruskal-Wallis test), and 3/3 (*χ*^2^ = 10.691, df = 2, *P* = .005, by Kruskal-Wallis test) copies of chr17/*TP53*was significantly different among cell lines. The Games-Howell posthoc analyses demonstrated that the ACP02 presented a higher frequency of cells with 2 copies of chr17 and loss of *TP53* than AGP01 (*P* = .001) and ACP03 (*P* = .001). In ACP02, the most common alteration observed was the loss of one copy of *TP53*([Figure 1(e)](#fig1){ref-type="fig"}).

Only ACP03 and AGP01 presented clonal chr17 trisomy with two or three copies of *TP53*. Thus, the Games-Howell posthoc analysis among cell lines also demonstrated that AGP01 and ACP03 presented a higher frequency of cells with chr17 trisomy with 2 *TP53* copies than ACP02 (*P* = .035 and *P* = .15, resp.; [Figure 1(f)](#fig1){ref-type="fig"}). AGP01 also presented a higher frequency of cells with chr17 trisomy and 3 *TP53* copies than ACP02 (*P* = .013).

Concerning the chr17 and *TP53* alterations during culture process, we observed that the frequency of cells with two copies of chr17/*TP53*(*χ*^2^ = 11.467, df = 4, *P* = .022, by Friedman test), two chr17 copies (*χ*^2^ = 10.373, df = 4, *P* = .035, by Friedman test), and chr17 trisomy (*χ*^2^ = 10.4, df = 4, *P* = .034, by Friedman test) were significantly different among parental tumor and their passages. However, the posthoc analysis by Wilcoxon test with Bonferroni correction did not reveal any significant difference, probably due to the gradual alterations among passages (Figures [2(e)](#fig2){ref-type="fig"}, [2(f)](#fig2){ref-type="fig"}, [2(g)](#fig2){ref-type="fig"}, [2(h)](#fig2){ref-type="fig"}).

4. Discussion {#sec4}
=============

Fluorescence *in situ*hybridization (FISH) assay allows rapid detection of numerical genetic aberrations in interphase nuclei in tumor cells. FISH assay should be used to evaluate cell-to-cell heterogeneity in gene or loci copy number and detect small subpopulations of genetically aberrant cells \[[@B16]\]. Using FISH assay, our research group previously reported several frequent aneusomies in GC samples and cell lines from individuals of Northern Brazil, which suggests a genomic instability \[[@B7], [@B12], [@B13], [@B17]--[@B20]\]. Molecular cytogenetic studies have shown that gains at 3q, 7p, 7q, 8q, 13q, 17q, 20p, and 20q and losses at 4q, 9p, 17p, and 18q are recurrent chromosomal alterations in GC. (For a review, see \[[@B21]\].)

Our research group has observed that chr8 trisomy, where *MYC* is located, is present in almost all gastric tumors and cell lines from our population by conventional and molecular cytogenetic analyses \[[@B7], [@B12], [@B13], [@B17], [@B19], [@B20], [@B22], [@B23]\]. We have previously described that ACP02, ACP03, and AGP01 at the 60th passage presented chr8 trisomy, as well as tetrasomy. In these cell lines, more than 5 signals of chr8 were observed in less than 5% of cells \[[@B12]\]. However, *MYC* copy number seems to be higher than the number of chr8 copies in our studies \[[@B19], [@B20], [@B23]\]. High *MYC* amplification has frequently been observed in primary tumors from our population, and we have also previously reported that *MYC* can be inserted into other chromosomes. The higher frequency of *MYC* high amplification in ACP03 and AGP01, originated from intestinal-type GC, than ACP02, originated from a diffuse-type GC, agrees with our previous observation in primary GC. Our group had observed that clonal high amplification of *MYC* is less frequent in diffuse-type than intestinal-type primary GC \[[@B19], [@B20], [@B23]\].

Thus, the presence of three or more copies of *MYC*, including gene high amplification, in all samples of the present study corroborates our previous observations in primary GC. Moreover, the frequency of *MYC* gain in advanced GC observed by FISH seems to be higher in our population than in East Asia, which ranges from 15.5% to 48% of cases \[[@B6], [@B24], [@B25]\]. *MYC* amplification has been suggested as the main mechanism for its deregulation in GC (see review \[[@B26]\]).

Concerning *TP53*/chr17 copies, we observed that ACP02, cell line, and its parental tumor, presented cells with two copies of chr17 and loss of one copy of *TP53*more frequently than ACP03 and AGP01. This finding corroborates our previous study using dual-color FISH for chr17/*TP53* in primary tumor samples, in which we observed that the frequency of cells with two chr17 and one *TP53* signals was higher in the diffuse-type than in the intestinal-type GC \[[@B27]\].

We also observed that only ACP03 and AGP01 cells and parental tumors presented chr17 trisomy as clonal alteration, in agreement with the karyotype of these cell lines at 60th passage \[[@B12]\]. Although primary tumors of individuals from Northern Brazil present clonal crh17 trisomy or monosomy by FISH analysis \[[@B27]\], chr17 aneusomy is not the most frequent alteration within primary tumors of our population \[[@B7], [@B22], [@B28]\].

Moreover, we detected *TP53* loss in all cell lines and primary tumors. *TP53* somatic alteration is described in about 50% of human cancers, including GC \[[@B29]\]. Deletion of chromosome arm 17p was also observed in ACP02, ACP03, and AGP01 by conventional cytogenetic analysis \[[@B12]\]. In our population, *TP53* deletion was previously observed in all analyzed primary tumor samples, despite Laurén\'s histopathologic types; therefore, corroborating the present study \[[@B27]\].

Although we did not observe any significant difference among parental tumors and their cell line passages after posthoc analysis, we were able to observe that the number of *MYC* signals is significantly higher in cell lines than primary tumors. We also observed a reduction in the number of nuclei with two signals for chr17/*TP53* when we compared GC cell lines with their parental tumors, which reflects an increase of aneusomy cells.

Tumor samples are usually composed of a heterogeneous clonal population which can include nonneoplastic cells. The increased frequency of cells with *MYC* gain, *TP53* loss, and chr17 trisomy in cell lines may be due to the selection of a subpopulation of cancer cells during the cell line establishment. Normal cells can divide only a limited number of times *in vitro*, because of replicative senescence. However, some tumor cells can become immortal and, therefore, they do not undergo senescence when cultured *in vitro*\[[@B30]\]. According to the Hayflick limit, the maximum number of passages that a normal cell attains before senescence is about 50 \[[@B31]\]. Here, we evaluated GC cell lines in the 60th and in 85th passages, which select cells with genomic alterations that are essential for cell survival and proliferation *in vitro*.

A meta-analysis of the studies using comparative genomic hybridization assay to evaluate chromosomal alterations in cancer cell lines and primary tumors demonstrated that, on average, the relatively large-scale copy number genetic aberrations seen in cell lines *in vitro* accurately reflect their parent histology \[[@B8]\]. In this meta-analysis study, it was also reported that *MYC* oncogene amplification seems to be more frequent in cell lines in several histologies, indicating that the deregulation of this gene may be acquired as part of cell immortalization or that their occurrence is selected when tumors are chosen for transformation. Therefore, we suggest that, in our GC cell lines, cells with *MYC* amplification are selected during the long culture process.

5. Conclusion {#sec5}
=============

Our findings reveal that ACP02, ACP03, and AGP01 cell lines retain *in vitro* the genetic alterations presented in their parental primary tumors. Thus, these findings suggest that these cell lines are an interesting model to study GC biology as well as to evaluate new anticancer strategies.
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![Fluorescence *in situ* hybridization assay. (a) Interphase nuclei presenting two *MYC* signals from normal gastric mucosa; (b) interphase nuclei presenting 2--5 *MYC* signals from ACP02 parental primary tumor; (c) interphase nuclei presenting *MYC* signal number alterations, including high amplification, from the 85th passage of AGP01 cell line; (d) interphase and metaphase cells presenting two copies of chr17/*TP53*from lymphocytes control, with the green spots representing the 17 centromere probe and the red representing the *TP53* gene probe; (e) interphase nuclei presenting two signals of chr17 and two or one *TP53*signal(s) from ACP02 parental primary tumor; (f) interphase nuclei presenting three signals for chr17 and two *TP53* signals from the 85th passage of ACP03 cell line.](JBB2011-631268.001){#fig1}

###### 

Distribution of cells according to (a) *MYC* signals in AGP01 parental tumor and cell line passages; (b) *MYC* signals in ACP02 parental tumor and cell line passages; (c) *MYC* signals in ACP03 parental tumor and cell line passages; (d) mean of *MYC* signals of AGP01, ACP02, and ACP03 parental tumor and cell line passages; (e) *TP53*/chr17 signals in AGP01 parental tumor and cell line passages; (f) *TP53*/chr17 signals in ACP02 parental tumor and cell line passages; (g) *TP53*/chr17 signals in ACP03 parental tumor and cell line passages; (h) mean of *TP53*/chr17 signals of AGP01, ACP02, and ACP03 parental tumor and cell line passages.
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###### 

FISH analysis of *MYC* copy number in gastric cancer cell lines, in their parental primary tumors and in control samples.

                                          Nuclei exhibiting *MYC* signals, no. (%)^a^                                                   
  -------------- ------------------------ --------------------------------------------- ----------- ----------- ----------- ----------- ----------
  ACP02          Parental primary tumor   0 (0)                                         57 (28.5)   78 (39)     57 (28.5)   8 (4)       0 (0)
  6th passage    1 (0.5)                  40 (20)                                       84 (42)     62 (31)     13 (6.5)    0(0)        
  12th passage   0 (0)                    34 (17)                                       88 (44)     63 (31.5)   15 (7.5)    0(0)        
  60th passage   0 (0)                    6 (3)                                         83 (41.5)   79 (39.5)   24 (12.5)   7 (3.5)     
  85th passage   2 (1)                    8 (4)                                         65 (32.5)   84 (42)     30 (15)     11 (5.5)    
                                                                                                                                        
  ACP03          Parental primary tumor   0 (0)                                         39 (19.5)   84 (42)     41 (20.5)   23 (11.5)   13 (6.5)
  6th passage    0(0)                     33 (16.5)                                     89 (44.5)   40 (20)     24 (12)     14 (7)      
  12th passage   1 (0.5)                  19 (9.5)                                      85 (42.5)   51 (25.5)   29 (14.5)   15 (7.5)    
  60th passage   1 (0.5)                  8 (4)                                         71 (35.5)   63 (31.5)   39 (19.5)   18 (9)      
  85th passage   0 (0)                    6 (3)                                         47 (23.5)   69 (34.5)   49 (24.5)   29 (14.5)   
                                                                                                                                        
  AGP01          Parental primary tumor   0 (0)                                         47 (23.5)   90 (45)     37 (18.5)   17 (8.5)    9 (4.5)
  6th passage    4 (2)                    12 (6)                                        69 (34.5)   59 (29.5)   36 (18)     20 (10)     
  12th passage   1 (0.5)                  13 (6.5)                                      70 (35)     56 (28)     33 (16.5)   27 (13.5)   
  60th passage   0 (0)                    2 (1)                                         64 (32)     63 (31.5)   41 (20.5)   30 (15)     
  85th passage   1 (0.5)                  1 (0.5)                                       45 (22.5)   67 (33.5)   49 (24.5)   37 (18.5)   
                                                                                                                                        
  Control        Normal stomach tissue    4 (2)                                         194 (97)    2 (1)       0 (0)       0 (0)       0 (0)
  Lymphocytes    1 (0.5)                  199 (99.5)                                    0 (0)       0 (0)       0 (0)       0 (0)       

^a^The FISH analysis was performed on 200 nuclei. HA: high amplification.

###### 

FISH analysis of chr17/*TP53* copy number in gastric cancer cell lines, in their parental primary tumors and in control samples.

                                          Nuclei exhibiting chr17/*TP53* signals, no. (%)^a^                                                                   
  -------------- ------------------------ ---------------------------------------------------- ----------- ------------ ------------ ------------ ------------ ----------
  ACP02          Parental primary tumor   3 (1.5)                                              4 (2)       63 (31.5)    130 (65)     0 (0)        0 (0)        0 (0)
  6th passage    2 (1)                    4 (2)                                                62 (31)     132 (66)     0 (0)        0 (0)        0 (0)        
  12th passage   0 (0)                    7 (3.5)                                              73 (36.5)   120 (60)     0 (0)        0 (0)        0 (0)        
  60th passage   1 (0.5)                  10 (5)                                               84 (42)     104 (52)     1 (0.5)      0 (0)        0 (0)        
  85th passage   2 (1)                    25 (12.5)                                            102 (51)    69 (34.5)    1 (0.5)      0 (0)        1 (0.5)      
                                                                                                                                                               
  ACP03          Parental primary tumor   2 (1)                                                14 (7)      17 (8.5)     100 (50)     0 (0)        54 (27)      13 (6.5)
  6th passage    3 (1.5)                  15 (7.5)                                             14 (7)      86 (43)      3 (1.5)      47 (23.5)    32 (16)      
  12th passage   4 (2)                    8 (4)                                                9 (4.5)     75 (37.5)    4 (2)        55 (27.5)    45 (22.5)    
  60th passage   1 (0.5)                  1 (0.5)                                              2 (1)       21 (10.5)    2 (1)        70 (35)      103 (51.5)   
  85th passage   3 (1.5)                  0 (0)                                                5 (2.5)     6 (3)        5 (2.5)      121 (60.5)   60 (30)      
                                                                                                                                                               
  AGP01          Parental primary tumor   6 (3)                                                29 (14.5)   7 (3.5)      116 (58)     4 (2)        12 (6)       26 (13)
  6th passage    5 (2.5)                  12 (6)                                               4 (2)       36 (18)      0 (0)        31 (15.5)    112 (56)     
  12th passage   0 (0)                    9 (4.5)                                              3 (1.5)     35 (17.5)    6 (3)        37 (18.5)    110 (55)     
  60th passage   4 (2)                    4 (2)                                                0 (0)       30 (15)      5 (2.5)      36 (18)      121 (60.5)   
  85th passage   3 (1.5)                  7 (3.5)                                              0 (0)       23 (11.5)    3 (1.5)      70 (35)      94 (47)      
                                                                                                                                                               
  Control        Normal stomach tissue    0 (0)                                                4 (2)       1 (0.5)      193 (96.5)   0 (0)        0 (0)        2 (1)
  Lymphocytes    0 (0)                    3 (1.5)                                              1 (0.5)     195 (97.5)   1 (0.5)      0 (0)        0 (0)        

^a^The FISH analysis was performed on 200 nuclei.
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